Back to Knowledge Center
Gastroenterology ICD-10: K72.90

Hepatic Encephalopathy

A reversible decline in brain function caused by severe liver disease, leading to confusion, altered sleep, and hand tremors as toxins (like ammonia) build up in the blood.

Source: AASLD Practice Guideline on Hepatic Encephalopathy
Updated: Aug 04, 2026
2,848 Views
Red Flag Warning & Emergency Situations
  • Inability to protect the airway (Grade III/IV HE) requiring immediate intubation before attempting NG tube placement for medication.

Emergency Management: Status epilepticus or acute intracranial hypertension causing brainstem herniation (Cushing's triad: hypertension, bradycardia, irregular breathing).

Core Definition:

Hepatic Encephalopathy (HE) is a potentially reversible, progressive neuropsychiatric syndrome occurring in patients with acute liver failure, liver cirrhosis, or portosystemic shunts. It manifests as a spectrum of cognitive, psychiatric, and motor disturbances ranging from subtle changes in personality and sleep-wake cycles to deep coma. It is primarily caused by the accumulation of neurotoxins, specifically ammonia, in the systemic circulation due to impaired hepatic clearance.

Detailed Overview

HE is a defining complication of decompensated cirrhosis. The diseased liver fails to convert gut-derived ammonia into urea, and portal hypertension causes blood to shunt around the liver entirely. The resulting elevated ammonia crosses the blood-brain barrier, disrupting astrocyte function. HE is rarely an unprovoked event; it is almost always triggered by a precipitating factor such as infection, GI bleeding, dehydration, or constipation. Identifying and treating the precipitating cause is as important as lowering ammonia levels. Its clinical significance is profound, as the onset of HE marks a transition to advanced liver disease and is a key indication for liver transplant evaluation.

Epidemiology & Demographics

Occurs in 30-40% of patients with cirrhosis at some point during their clinical course. Minimal HE (covert) affects up to 80% of patients with cirrhosis. It is a major cause of hospital readmissions.

Etiological Mechanism

The foundational etiology is hepatocellular failure and/or the presence of portosystemic shunts (either spontaneous varices or iatrogenic like TIPS - Transjugular Intrahepatic Portosystemic Shunt). This creates the anatomical and physiological setup for HE. The acute episodes are driven by precipitants.

Primary Causes

Precipitants: Infections (Spontaneous Bacterial Peritonitis, UTI), Gastrointestinal bleeding (massive protein load in the gut), Constipation, Hypokalemia/Alkalosis (increases ammonia entry into brain), Dehydration/Diuretics, and CNS depressant drugs (benzodiazepines, opioids).

  • TIPS Procedure: Creation of a portosystemic shunt dramatically diverts portal blood away from the liver, significantly increasing the risk of HE.
  • Sarcopenia: Loss of muscle mass removes a critical alternative site for ammonia detoxification (muscle synthesizes glutamine from ammonia).

Ammonia is produced in the colon by bacterial metabolism of dietary protein and urea. Normally, the liver rapidly clears it via the urea cycle. In cirrhosis, portosystemic shunting and hepatocyte dysfunction allow ammonia to bypass liver metabolism and enter systemic circulation. Ammonia readily crosses the blood-brain barrier. Astrocytes take up ammonia and convert it to glutamine via glutamine synthetase. Massive glutamine accumulation acts as an intracellular osmolyte, causing astrocyte swelling and cerebral edema (severe in acute liver failure, low-grade in cirrhosis). This astrocytopathy disrupts neurotransmission, altering GABAergic tone (increasing neuroinhibition) and causing mitochondrial dysfunction and oxidative stress, manifesting clinically as encephalopathy.

Characteristic Clinical Presentation

  • Altered Sleep-Wake Cycle: Often the earliest symptom; patients are awake and restless at night and somnolent during the day.
  • Cognitive Impairment: Poor concentration, confusion, personality changes, and inappropriate behavior.
  • Motor Impairment: Slurred speech, sluggish movements, and poor coordination.

Physical Examination Signs

  • Asterixis (Flapping Tremor): Elicited by having the patient hold their arms outstretched with wrists dorsiflexed; characterized by rapid, non-rhythmic lapses of posture.
  • Fetor Hepaticus: A sweet, musty breath odor caused by exhaled dimethyl sulfide.
  • Hyperreflexia and rigidity in early stages; progressing to flaccidity in deep coma.
Clinical Risk: Uncontrolled or untreated conditions may progress to the following complications:
  • Cerebral Edema: Particularly dangerous in acute liver failure, leading to uncal herniation and brain death.
  • Aspiration Pneumonia: Due to depressed level of consciousness and loss of airway reflexes.

Diagnostic Criteria & Guidelines

A clinical diagnosis based on the presence of altered mental status in a patient with known liver disease or portosystemic shunts, after excluding other metabolic, infectious, or intracranial causes of encephalopathy.

Differential Diagnosis

  • Subdural Hematoma (common in cirrhotics due to coagulopathy and falls)
  • Wernicke Encephalopathy
  • Sepsis-Associated Encephalopathy

Laboratory Tests & Biomarkers

  • Serum Ammonia: Typically elevated (> 80 µmol/L), but levels DO NOT correlate well with the clinical severity of encephalopathy and are not required for diagnosis.
  • Comprehensive Metabolic Panel: Evaluate for precipitants: hypokalemia, hyponatremia, elevated BUN/Creatinine (AKI).

Imaging Modalities & Findings

  • CT Head:
  • Grade I (Covert)
    Trivial lack of awareness, altered sleep, mild personality changes. No asterixis.
  • Grade II
    Lethargy, apathy, disorientation to time. Asterixis is present.
  • Grade III
    Somnolent but arousable, gross disorientation, bizarre behavior.
  • Grade IV
    Unarousable, unresponsiveness. May have decerebrate posturing.
First-Line Treatment:

Lactulose (Non-absorbable disaccharide). Starting dose: 20-30 grams (30-45 mL) PO or via NG tube every 1-2 hours until a bowel movement occurs, then titrate to achieve 2-3 soft bowel movements daily. Lactulose lowers colonic pH, trapping ammonia as unabsorbable ammonium (NH4+), and acts as a cathartic to clear nitrogenous load. MUST actively search for and treat the precipitant (e.g., pan-culture and start antibiotics if SBP suspected).

Second-Line & Adjunctive Therapy

Rifaximin (Non-absorbable antibiotic) 550 mg PO BID. Added to Lactulose for patients who do not respond to Lactulose alone or for secondary prophylaxis after a recurrent episode. Rifaximin alters gut microbiota, reducing ammonia-producing bacteria.

Surgical & Procedural Management

Liver transplantation is the only definitive cure for the underlying hepatic dysfunction. Embolization of large spontaneous portosystemic shunts is sometimes performed in refractory cases.

Recommended Lifestyle Changes

  • Avoid dietary protein restriction; cirrhotics are often malnourished and need 1.2-1.5 g/kg/day of protein. Vegetable/dairy proteins are preferred over meat.
  • Strict avoidance of alcohol and sedative medications (benzodiazepines, sleeping pills).

Patient Counseling & Advice

Educate caregivers that confusion is a sign of medical urgency, not just 'acting out.' Ensure they understand Lactulose dosing is titrated to effect (2-3 soft stools/day), not a strict fixed dose.

Follow-Up & Monitoring Schedule

Monitor clinical mental status and frequency of bowel movements daily. Routine measuring of serum ammonia to monitor treatment response is NOT recommended.

Preventive Strategies

Secondary prophylaxis with Lactulose (and Rifaximin if recurrent). Maintaining daily bowel movements and prompt treatment of infections.

The development of overt HE carries a poor prognosis, with a 1-year survival rate of approximately 40% without liver transplantation.

Frequently Asked Questions

No. Malnutrition is very dangerous in cirrhosis. While a sudden massive intake of meat can trigger an episode, patients need adequate protein to maintain muscle mass, which actually helps remove ammonia.
Authoritative Sources & Evidence References
AASLD Practice Guideline on Hepatic Encephalopathy:
View Official Guideline
Key Literature & References:
Evidence Rifaximin Treatment in Hepatic Encephalopathy

System Notice

Confirm Action